Sugi Predict

Sugi Predict / Targets / UBAP2

UBAP2

Ubiquitin-associated protein 2 · Q5T6F2 · UBAP2 on Sugi Atlas →

0 patent compounds predicted against UBAP2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to UBAP2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
A Trial of Levodopa in Angelman Syndrome PHASE2/PHASE3COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer PHASE1/PHASE2COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
The Significance of Urine UbA52 In the Diagnosis of Diabetic Nephropathy nanCOMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS nanRECRUITING
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit nanCOMPLETED
Using Mobile Technology to Improve Self-Regulation nanCOMPLETED
Autophagy Bladder Cancer nanUNKNOWN
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease nanUNKNOWN
Gene Analysis of Parkinson's Disease nanCOMPLETED
The Relation of Microtubule-Associated Protein 2 and Cell Migration nanUNKNOWN
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC) nanUNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients nanUNKNOWN
Family Blood Pressure Program - GenNet Network nanCOMPLETED
Whole Genome Scan of Extended Families With Familial Vocal Cord Paralysis nanCOMPLETED
New Strategies of Genetic Study of Patients With Oculocutaneous Albinism nanCOMPLETED
Identification of a New Gene Involved in Hereditary Lipodystrophy nanCOMPLETED
Delineation of Novel Monogenic Disorders in the United Arab Emirates Population nanUNKNOWN
The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma nanWITHDRAWN
Identification of New FTLD Genes nanUNKNOWN
Study of a Candidate Gene Involved in Goldenhar Syndrome. nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a UBAP2 binder may also engage these)

ProteinNameSimilarity
Q91VX2 — 1.000 Q91VX2 →
UBAP2L Ubiquitin-associated protein 2-like 0.996 landscape →
Q80X50 — 0.991 Q80X50 →
P51514 — 0.982 P51514 →
Q9NRA8 — 0.981 Q9NRA8 →
Q61286 — 0.979 Q61286 →
Q80TM6 — 0.979 Q80TM6 →
A0A0R4IBL7 — 0.979 A0A0R4IBL7 →
Q9Y2K5 — 0.979 Q9Y2K5 →
Q64028 — 0.978 Q64028 →
Q9EST3 — 0.978 Q9EST3 →
RBM26 RNA-binding protein 26 0.977 landscape →
Q8VHG2 — 0.977 Q8VHG2 →
P78364 — 0.977 P78364 →
P16951 — 0.977 P16951 →
Q9UMZ2 — 0.976 Q9UMZ2 →
Q6NZN0 — 0.976 Q6NZN0 →
O09000 — 0.976 O09000 →
Q9P2N5 — 0.976 Q9P2N5 →
P98180 — 0.976 P98180 →
P70365 — 0.976 P70365 →
A5D7F6 — 0.976 A5D7F6 →
Q9DCB4 — 0.976 Q9DCB4 →
Q62415 — 0.976 Q62415 →
A0A087WPF7 — 0.975 A0A087WPF7 →
P15336 — 0.975 P15336 →
P30985 — 0.975 P30985 →
Q5R4R4 — 0.975 Q5R4R4 →
TCF12 Transcription factor 12 0.975 landscape →
TCF4 Transcription factor 4 (TCF-4) (Class B basic 0.975 landscape →